Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Arthritis, Juvenile: later-stage trial registry
1 of 3 indexed Arthritis, Juvenile trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Arthritis, Juvenile: 3 US clinical trials tracked, 1 recruiting.
Arthritis, Juvenile is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Janssen Research & Development, running 3 of these trials.
Enrollment posture brief
Registry condition arthritis-juvenile
OPEN 1 | RECR 33% | LATE 3 | EARLY 0 | RANK #5209 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Arthritis, Juvenile lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Arthritis, Juvenile on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Arthritis, Juvenile is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Janssen Research & Development
NCT06663332
A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis
Janssen Research & Development
NCT05083182
A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy
Janssen Research & Development
NCT02277444
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Arthritis, Juvenile records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Arthritis, Juvenile trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Arthritis, Juvenile page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Arthritis, Juvenile trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Janssen Research & Development sponsors the most Arthritis, Juvenile trials on record, review their full trial history before evaluating a specific study. See Janssen Research & Development's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Arthritis, Juvenile condition card totals 3 registered trials; most-linked intervention Guselkumab; top US site state Utah. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.